Last reviewed · How we verify
NCT07532746
A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies
Phase 1 trial testing KSD-101 in Relapsed or Refractory EBV-associated Hematological Malignancies in 55 participants. Not yet recruiting.
31 December 2028
Quick facts
| Lead sponsor | Kousai Bio Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 55 |
| Start date | 1 May 2026 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2029 |
| Sites | 2 locations across China |
Drugs / interventions tested
- KSD-101 — full drug profile →
Conditions studied
- Relapsed or Refractory EBV-associated Hematological Malignancies — all drugs for Relapsed or Refractory EBV-associated Hematological Malignancies →
Sponsor
Kousai Bio Co., Ltd. — full company profile →
Who can join
Adults 2 to 70, any sex, with Relapsed or Refractory EBV-associated Hematological Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpse of this study is to evaluate the safety and tolerability of KSD-101 in the treatment of relapsed or refractory EBV-associated hematological malignancies,to preliminarily explore the clinical efficacy ,evaluate the immune response to KSD-101 for the treatment in Patients with EBV-associated hematological diseases and the improvement in subjects' quality of life (QOL) after KSD-101 treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07532746
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of KSD-101
Trials testing the same drug.
- NCT06752473 — KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial · EARLY_PHASE1 · not yet recruiting
- NCT06370026 — KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial · EARLY_PHASE1 · not yet recruiting
- NCT06097793 — KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial · EARLY_PHASE1 · unknown
Other Kousai Bio Co., Ltd. trials
Trials by the same sponsor.
- NCT06708936 — KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study · EARLY_PHASE1 · not yet recruiting
- NCT06752473 — KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial · EARLY_PHASE1 · not yet recruiting
- NCT06097793 — KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial · EARLY_PHASE1 · unknown
- NCT05882305 — KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial · EARLY_PHASE1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07532746 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kousai Bio Co., Ltd.
- Last refreshed: 16 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07532746.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing